

Table 30: Clinical evidence profile: Comparison 1. Single IV agents compared for pulmonary exacerbations with *P aeruginosa*

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Single IV agent	Single IV agent	Relative (95% CI)	Absolute		
FEV₁ (absolute change) (follow-up 2 weeks; measured with: litres ; Better indicated by higher values) [ceftazidime versus aztreonam]												
2 (Elborn 1992, Salh 1992)	randomised trials	serious ¹	serious ²	no serious indirectness	no serious imprecision	none	23	23	-	MD 0.06 lower (0.44 lower to 0.32 higher)	LOW	CRITICAL

Abbreviations: CI: confidence interval; FEV₁: forced expiratory volume in 1 second; MD: mean difference

1 The quality of the evidence was downgraded by 1 as 4 participants received both drugs in Salh 1992 study,

2 The quality of the evidence was downgraded by 1 due to serious heterogeneity (chi-squared $p < 0.1$, I-squared inconsistency statistic of 50%-74.99%)